Observational studyThrombosis and haemostasis2017
The management of acute venous thromboembolism in clinical practice. Results from the European PREFER in VTE Registry.
Observational study in Thrombosis and haemostasis, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 2 syntheses or guidelines pooled it, 84 citations in OpenAlex.
- Evaluation of venous thromboembolism risk assessment models for hospital inpatients: the VTEAM evidence synthesis.Health technology assessment (Winchester, England) · 2024Pooled it
- Different strategies for pharmacological thromboprophylaxis for lower-limb immobilisation after injury: systematic review and economic evaluation.Health technology assessment (Winchester, England) · 2019Pooled it
- Α 6-month, multicenter, observational study investigating the treatment of venous thromboembolism in Greece (VICTORIA study).Thrombosis journal · 2025Article
- Temporal trend in venous thromboembolism hospitalization rates in Brazil.Revista da Associacao Medica Brasileira (1992) · 2025Article
- Effectiveness and cost effectiveness of pharmacological thromboprophylaxis for medical inpatients: decision analysis modelling study.BMJ medicine · 2024Article
- Mechanical thrombectomy is associated with shorter length of hospital stay and lower readmission rates compared with conservative therapy for acute submassive pulmonary embolism: a propensity-matched analysis.Diagnostic and interventional radiology (Ankara, Turkey) · 2023Article
- Contemporary Management and Clinical Course of Acute Pulmonary Embolism: The COPE Study.Thrombosis and haemostasis · 2023Article
- Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk score.European heart journal · 2023Article
- D-Dimer beyond Diagnosis of Pulmonary Embolism: Its Implication for Long-Term Prognosis in Cardio-Oncology Era.Journal of personalized medicine · 2023Article
- Cost-of-Illness Analysis of Long-Term Health Care Resource Use and Disease Burden in Patients With Pulmonary Embolism: Insights From the PREFER in VTE Registry.Journal of the American Heart Association · 2022Article
- The venous thrombosis registry in Østfold Hospital (TROLL registry) - design and cohort description.Research and practice in thrombosis and haemostasis · 2022Article
- VENOUS THROMBOEMBOLISM IN THE EMERGENCY DEPARTMENT - SINGLE-CENTER EXPERIENCE.Acta clinica Croatica · 2022Article
- Contemporary clinical management of acute pulmonary embolism: the COPE study.Internal and emergency medicine · 2022Article
- Pulmonary embolism in patients with COVID-19 pneumonia on adequate oral anticoagulation.Journal of thrombosis and thrombolysis · 2022Article
- Effectiveness and safety of direct oral anticoagulants with antiplatelet agents in patients with venous thromboembolism: A multi-database cohort study.Research and practice in thrombosis and haemostasis · 2022Article
- Clinical epidemiology of venous thromboembolic disease: An institutional registry.Frontiers in cardiovascular medicine · 2022Article
- Cancer-Associated ThrOmboSIs - Patient-Reported OutcoMes With RivarOxaban (COSIMO) - Baseline characteristics and clinical outcomes.Research and practice in thrombosis and haemostasis · 2021Article
- Is pulmonary embolism recurrence linked with the severity of the first event? A French retrospective cohort study.BMJ open · 2021Article
- Management of isolated distal deep-vein thrombosis with direct oral anticoagulants in the RIETE registry.Journal of thrombosis and thrombolysis · 2021Article
- Anticoagulant treatment for venous thromboembolism: A pooled analysis and additional results of the XALIA and XALIA-LEA noninterventional studies.Research and practice in thrombosis and haemostasis · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 9 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Venous thromboembolism (VTE) is a significant cause of morbidity and mortality in Europe. Data from real-world registries are necessary, as clinical trials do not represent the full spectrum of VTE patients seen in clinical practice. We aimed to document the epidemiology, management and outcomes of VTE using data from a large, observational database. PREFER in VTE was an international, non-interventional disease registry conducted between January 2013 and July 2015 in primary and secondary care across seven European countries. Consecutive patients with acute VTE were documented and followed up over 12 months. PREFER in VTE included 3,455 patients with a mean age of 60.8 ± 17.0 years. Overall, 53.0 % were male. The majority of patients were assessed in the hospital setting as inpatients or outpatients (78.5 %). The diagnosis was deep-vein thrombosis (DVT) in 59.5 % and pulmonary embolism (PE) in 40.5 %. The most common comorbidities were the various types of cardiovascular disease (excluding hypertension; 45.5 %), hypertension (42.3 %) and dyslipidaemia (21.1 %). Following the index VTE, a large proportion of patients received initial therapy with heparin (73.2 %), almost half received a vitamin K antagonist (48.7 %) and nearly a quarter received a DOAC (24.5 %). Almost a quarter of all presentations were for recurrent VTE, with >80 % of previous episodes having occurred more than 12 months prior to baseline. In conclusion, PREFER in VTE has provided contemporary insights into VTE patients and their real-world management, including their baseline characteristics, risk factors, disease history, symptoms and signs, initial therapy and outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.